NVO - Wegovy's Precarious Position: 3 Drugs Most Likely to Dethrone Novo Nordisk's Blockbuster Obesity Drug
2024-06-14 05:50:00 ET
Novo Nordisk 's (NYSE: NVO) Wegovy currently reigns as the king of the obesity drug market. It generated roughly $4.5 billion in sales last year and will likely rake in even more in 2024.
But note the use of the word "currently." Wegovy's market-topping position is precarious. Here are three drugs most likely to dethrone Novo Nordisk's blockbuster drug .
Eli Lilly (NYSE: LLY) won U.S. regulatory approval for Zepbound in helping patients lose weight in November 2023. In the first quarter of 2024, the sales for Lilly's obesity drug topped $517 million.
For further details see:
Wegovy's Precarious Position: 3 Drugs Most Likely to Dethrone Novo Nordisk's Blockbuster Obesity Drug